dBET57 is a novel BRD4 heterobifunctional small-molecule ligand (PROTAC), exhibits significant and selective degradation of BRD4 BD1 (DC50/5h=500 nM), but is inactive on BRD4 BD2..

FB23-2 is a potent, selective inhibitor of the mRNA N 6-methyladenosine (m 6A) demethylase FTO, directly bind to FTO, inhibits FTO demethylation of m6 A in RNA in vitro with IC50 of 2.6 uM.

JNJ303 is a potent, specific delayed rectifier potassium current I(Ks) blocker with IC50 of 64 nM, shows no effects on other cardiac channels (IC50=3.3, >10, 11.1 and 12.6 uM for Na, ICa, Ito and IKr currents).

A novel potent, selective KCNQ2/Q3 (Kv7.2/Kv7.3) potassium channel opener/activator with EC50 of 0.38 uM..

A potent and highly selective JAK3 inhibitor with IC50 of 0.15 nM.

YTX-465 (YTX465) is a specific small molecule that rescues yeast from a-Syn cytotoxicity with EC50 of 15 nM, via inhibiting Ole1, the yeast homolog of human stearoyl-CoA desaturase (SCD).

SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.

SR-1664 is a novel potent, non-agonist PPARγ ligand that blocks the Cdk5-mediated phosphorylation in vitro (IC50=80 nM) and in vivo, without the classical agonism.

Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.

T-26c is highly potent and selective matrix metalloproteinase-13 (MMP-13) inhibitor with an IC50 of 6.75 pM and more than 2600-fold selectivity over the other related metalloenzymes.

GSK484 is a reversible inhibitor of PAD4 (IC50 = 50 nM) that binds to the low-calcium form of the enzyme.

#N/A

#N/A

DBCO-Biotin is a Click Chemistry intermidate used for antibody-drug conjugates..

Lixisenatide is a GLP-1 agonist for the treatment of diabetes type II.

Ravidasvir (PPI-668;BI 238630) is a potent pan-genotypic HCV NS5A inhibitor with IC50 of 0.12/0.01/1.14 nM for HCV gt-1a/1b/3a in replicon luciferase assay;

PF-06700841 is an inhibitor of JAK1 and TYK2 kinases. PF-06700841 has been investigated for the treatment of psoriasis and lupus.

Indotecan(LMP400) is a novel selective and potent topoisomerase I inhibitor with potential anticancer activitity.

HS-10296 is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity.

BI-1347 is a potent, selective inhibitor of CDK8/cyclinC with IC50 of 1 nM.

AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

AER-271 (AER271) is a selective, small molecule inhibitor of aquaporin-4 (AQP4), the prodrug of AER-270 with enhanced solubility.

FG 7142 (ZK 39106; LSU-65), a non-selectively benzodiazepine inverse agonist, has high affinity for the α1 subunit-containing GABAA receptor (Ki=91 nM). FG 7142 (ZK 39106; LSU-65) also modulates GABA-induced chloride flux at GABAA receptors expressing the

MBX2329 is a small molecule inhibitor of influenza virus H1N1 hemagglutinin.

XP-59 is a potent inhibitor of the SARS-CoV Mpro, with a Ki of 0.1 μM[1].The SARS-CoV main proteinase (Mpro) plays a central role in the formation of the viral replicase/transcriptase complex and is thus an ideal target for the development of suitable dru

LYS-006 is a novel leukotriene A4 hydrolase inhibitor.

BAY-474 is a tyrosine-protein kinase c-Met inhibitor. BAY-474 acts as an epigenetics probe.

MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.

Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders.

SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.